Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

We assessed safety and efficacy of rituximab in a prospective study of 36 patients, age 2.6 to 18.3 years, with severe chronic immune thrombocytopenic purpura (ITP). The primary outcome of sustained platelets above 50 × 10(9)/L (50 000/mm(3)) during 4 consecutive weeks, starting in weeks 9 to 12, wa...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bennett, Carolyn M., Rogers, Zora R., Kinnamon, Daniel D., Bussel, James B., Mahoney, Donald H., Abshire, Thomas C., Sawaf, Hadi, Moore, Theodore B., Loh, Mignon L., Glader, Bertil E., McCarthy, Maggie C., Mueller, Brigitta U., Olson, Thomas A., Lorenzana, Adonis N., Mentzer, William C., Buchanan, George R., Feldman, Henry A., Neufeld, Ellis J.
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society of Hematology 2006
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895391/
https://ncbi.nlm.nih.gov/pubmed/16352811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-08-3518
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky